Matching articles for "age-related macular degeneration"

Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • January 22, 2024;  (Issue 1694)
The FDA has approved the complement C5 inhibitor avacincaptad pegol (Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration...
The FDA has approved the complement C5 inhibitor avacincaptad pegol (Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad pegol is the second complement inhibitor to be approved in the US for this indication; pegcetacoplan (Syfovre), a complement C3 and C3b inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 | Show Full IntroductionHide Full Introduction

Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • April 3, 2023;  (Issue 1673)
The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series...
The FDA has approved the complement C3 inhibitor pegcetacoplan (Syfovre – Apellis) for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Given as a series of monthly or every-other-month (EOM) intravitreal injections, it is the first drug to become available for use in patients with atrophic dry AMD. Subcutaneous pegcetacoplan was approved earlier as Empaveli for treatment of paroxysmal nocturnal hemoglobinuria.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):49-50 | Show Full IntroductionHide Full Introduction

A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • May 2, 2022;  (Issue 1649)
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet)...
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz), a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Med Lett Drugs Ther. 2022 May 2;64(1649):71-2 | Show Full IntroductionHide Full Introduction

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • March 21, 2022;  (Issue 1646)
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 | Show Full IntroductionHide Full Introduction

Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • March 9, 2020;  (Issue 1593)
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported...
We reviewed brolucizumab (Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):40 | Show Full IntroductionHide Full Introduction

Brolucizumab (Beovu) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • February 10, 2020;  (Issue 1591)
Brolucizumab-dbll (Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related...
Brolucizumab-dbll (Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). It is the fourth VEGF inhibitor to be approved in the US for this indication; bevacizumab (Avastin, and others), a VEGF inhibitor FDA-approved for treatment of breast cancer and other malignancies, has been used off-label for this indication for years.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):23-4 | Show Full IntroductionHide Full Introduction

Drugs for Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • December 2, 2019;  (Issue 1586)
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate...
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.
Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-94 | Show Full IntroductionHide Full Introduction

VEGF Inhibitors for AMD and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • March 16, 2015;  (Issue 1464)
Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases...
Vascular endothelial growth factor (VEGF) is a principal mediator of neovascularization in wet age-related macular degeneration (AMD) and diabetic macular edema. It induces angiogenesis and increases vascular permeability and inflammation. VEGF inhibitors reduce leakage from blood vessels, prevent proliferation of new abnormal vessels, decrease swelling of the retina, and improve visual acuity in patients with neovascular (wet) AMD and diabetic macular edema. These drugs are given as periodic intravitreal injections with topical anesthesia.
Med Lett Drugs Ther. 2015 Mar 16;57(1464):41-2 | Show Full IntroductionHide Full Introduction

Nutritional Supplements for Age-Related Macular Degeneration Revisited

   
The Medical Letter on Drugs and Therapeutics • June 24, 2013;  (Issue 1419)
The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published. The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and...
The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published. The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and the omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in reducing the risk of developing advanced age-related macular degeneration (AMD). A secondary goal was to test the effects of reducing the amount of zinc and eliminating beta carotene from the original AREDS formulation. Beta carotene has been shown to increase the risk of lung cancer in smokers and former smokers.
Med Lett Drugs Ther. 2013 Jun 24;55(1419):50-1 | Show Full IntroductionHide Full Introduction

Drugs for Some Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • November 1, 2012;  (Issue 123)
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue...
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Treat Guidel Med Lett. 2012 Nov;10(123):79-86 | Show Full IntroductionHide Full Introduction

Aflibercept (Eylea) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • February 6, 2012;  (Issue 1383)
The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration...
The FDA has approved aflibercept (a flib’ er sept; Eylea – Regeneron) for treatment of neovascular (wet) age-related macular degeneration (AMD).
Med Lett Drugs Ther. 2012 Feb 6;54(1383):9-10 | Show Full IntroductionHide Full Introduction

Nutritional Support for Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • August 9, 2010;  (Issue 1344)
An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new...
An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new product] builds on the original PreserVision Eye Vitamin AREDS Formula, the only formula proven to slow the progression of moderate-to-advanced AMD.”
Med Lett Drugs Ther. 2010 Aug 9;52(1344):63 | Show Full IntroductionHide Full Introduction

Drugs for Some Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • January 1, 2010;  (Issue 89)
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly...
Drugs for glaucoma, age-related macular degeneration, bacterial conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves. Drugs for the treatment of allergic conjunctivitis will be reviewed in a future issue of Treatment Guidelines on Drugs for Allergic Disorders.
Treat Guidel Med Lett. 2010 Jan;8(89):1-8 | Show Full IntroductionHide Full Introduction

Drugs for Some Common Eye Disorders

   
The Medical Letter on Drugs and Therapeutics • January 1, 2007;  (Issue 53)
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some...
Drugs for glaucoma, age-related macular degeneration, bacterial and allergic conjunctivitis, and dry eyes are reviewed here. Ophthalmic drugs can have local and systemic adverse effects. In addition, for some elderly patients, the complexity of self-administering numerous ophthalmic drugs may be the limiting factor in their ability to care for themselves.
Treat Guidel Med Lett. 2007 Jan;5(53):1-8 | Show Full IntroductionHide Full Introduction

Ranibizumab (Lucentis) for Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • October 23, 2006;  (Issue 1246)
The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab...
The FDA has approved ranibizumab (Lucentis - Genentech) as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). Ranibizumab is a derivative of bevacizumab (Avastin), which is FDA-approved for intravenous treatment of metastatic colorectal cancer and nonsmall cell lung cancer, but has also been used off label for intravitreal treatment of neovascular AMD.
Med Lett Drugs Ther. 2006 Oct 23;48(1246):85-6 | Show Full IntroductionHide Full Introduction

Antioxidant Vitamins and Zinc for Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • June 8, 2003;  (Issue 1158)
High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision), "promote retinal and visual health" (VisiVite) and...
High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision), "promote retinal and visual health" (VisiVite) and "preserve healthy vision" (ICaps). Internet advertisements for these products all refer to a clinical trial, the Age-Related Eye Disease Study (AREDS), which was conducted in patients with age-related macular degeneration (AMD).
Med Lett Drugs Ther. 2003 Jun 8;45(1158):45-6 | Show Full IntroductionHide Full Introduction